Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and Novo Nordisk A/S. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$745.72 -9.39 (-1.24%)
As of 03:58 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The company recently reported a significant increase in quarterly revenue, showcasing a strong growth trajectory that could lead to higher future earnings.
  • Eli Lilly and Co has a high return on equity, indicating effective management and profitability, which can be attractive to investors looking for solid financial performance.
  • The current stock price is around $720, which may present a buying opportunity for investors looking to enter at a favorable valuation.

Cons of Eli Lilly and Company

  • The company recently missed earnings expectations, which could raise concerns about its ability to meet future financial targets.
  • There has been a downgrade in price targets by some analysts, indicating potential caution regarding the stock's future performance.
  • The payout ratio is relatively high, which may suggest that a significant portion of earnings is being distributed as dividends, potentially limiting reinvestment in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$706.75 billion
P/E Ratio
63.68
Consensus Rating
Moderate Buy
Consensus Price Target
$1,011.37 (+35.6% Upside)
Volume
3.87 million shares
Average Volume
3.60 million shares
Today's Range
$743.00
$763.50
50-Day Range
$716.19
$899.78
52-Week Range
$677.09
$972.53
Dividend Yield
0.84%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$153.58 +1.09 (+0.71%)
As of 03:58 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The company recently reported earnings per share of $2.77, exceeding expectations, which indicates strong financial performance and potential for growth.
  • Johnson & Johnson has a robust return on equity of 34.24%, suggesting effective management and profitability, which can be attractive to investors looking for solid returns.
  • The current stock price is around $165, reflecting a stable investment opportunity in the healthcare sector.

Cons of Johnson & Johnson

  • Recent insider selling, including significant transactions by executives, may raise concerns about the company's future performance and insider confidence.
  • Some analysts have downgraded the stock's rating, which could indicate potential challenges ahead and affect investor sentiment negatively.
  • The company's payout ratio is 57.84%, which, while manageable, suggests that a significant portion of earnings is being distributed as dividends, potentially limiting reinvestment in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$369.52 billion
P/E Ratio
23.09
Consensus Rating
Moderate Buy
Consensus Price Target
$170.88 (+11.3% Upside)
Volume
7.34 million shares
Average Volume
7.97 million shares
Today's Range
$152.12
$154.04
50-Day Range
$146.39
$165.89
52-Week Range
$140.68
$169.99
Dividend Yield
3.39%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$184.75 -0.96 (-0.52%)
As of 03:59 PM Eastern

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • The current stock price is around $185.64, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • AbbVie reported earnings per share (EPS) of $2.46 for the latest quarter, surpassing analysts' expectations, which suggests strong financial performance and potential for future growth.
  • The company achieved a revenue of $13.34 billion in the last quarter, exceeding estimates, indicating robust sales and operational efficiency.

Cons of AbbVie

  • The company has a relatively high price-to-earnings (P/E) ratio of 77.35, which may suggest that the stock is overvalued compared to its earnings.
  • AbbVie has a current ratio of 0.66, indicating potential liquidity issues, as it may struggle to cover short-term liabilities with its current assets.
  • Insider selling activity has been notable, with executives selling significant shares, which could raise concerns about their confidence in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$326.34 billion
P/E Ratio
76.98
Consensus Rating
Moderate Buy
Consensus Price Target
$210.95 (+14.2% Upside)
Volume
5.50 million shares
Average Volume
6.24 million shares
Today's Range
$183.64
$186.00
50-Day Range
$170.01
$214.45
52-Week Range
$153.58
$218.66
Dividend Yield
3.70%
Novo Nordisk A/S stock logo

4. Novo Nordisk A/S NYSE:NVO

$68.17 +1.15 (+1.72%)
As of 03:58 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $64.71, which may present a buying opportunity for investors looking for value.
  • Analysts have a consensus rating of "Moderate Buy" for Novo Nordisk, indicating positive sentiment among market experts.
  • The company reported strong quarterly earnings, meeting analysts' expectations with an earnings per share (EPS) of $0.92, showcasing its profitability.

Cons of Novo Nordisk A/S

  • The stock price has recently declined by about 1.1%, which may indicate short-term volatility and investor uncertainty.
  • Analysts have adjusted price targets downward, with one notable reduction from $105.00 to $64.00, suggesting potential challenges ahead.
  • The company has a quick ratio of 0.55, indicating that it may struggle to meet short-term liabilities without selling inventory.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$305.91 billion
P/E Ratio
20.72
Consensus Rating
Hold
Consensus Price Target
$135.00 (+98.0% Upside)
Volume
12.55 million shares
Average Volume
6.62 million shares
Today's Range
$67.65
$70.00
50-Day Range
$57.99
$80.95
52-Week Range
$57.00
$148.15
Dividend Yield
2.48%
UnitedHealth Group stock logo

5. UnitedHealth Group NYSE:UNH

$321.76 +5.87 (+1.86%)
As of 03:58 PM Eastern

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The company recently reported a revenue of approximately $109.58 billion, showcasing its strong market presence and operational scale.
  • UnitedHealth Group has a solid annualized dividend of $8.40, providing a dividend yield of about 2.78%, which can be attractive for income-focused investors.
  • Institutional investors hold a significant portion of the company’s stock, indicating strong confidence in its future performance, with over 87% of shares owned by these entities.

Cons of UnitedHealth Group

  • The company’s recent revenue fell short of analyst estimates, which could raise concerns about its growth trajectory and market competitiveness.
  • Despite a strong dividend, the payout ratio is approximately 35.18%, which may limit future dividend increases if earnings do not grow as expected.
  • Insider ownership is relatively low at 0.33%, which might suggest a lack of alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$291.88 billion
P/E Ratio
20.76
Consensus Rating
Moderate Buy
Consensus Price Target
$451.43 (+40.3% Upside)
Volume
41.22 million shares
Average Volume
6.24 million shares
Today's Range
$312.58
$324.64
50-Day Range
$273.96
$599.10
52-Week Range
$248.88
$630.73
Dividend Yield
2.73%
Novartis stock logo

6. Novartis NYSE:NVS

$112.30 +1.59 (+1.44%)
As of 03:58 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • Recent upgrades from analysts, including a "strong-buy" rating from StockNews.com, indicate positive market sentiment towards Novartis AG.
  • The current stock price is around $105.50, which is near its 1-year low of $96.06, potentially offering a buying opportunity for investors looking for value.
  • Institutional investors and hedge funds own 13.12% of Novartis AG's stock, suggesting confidence from large financial entities in the company's future performance.

Cons of Novartis

  • Despite recent upgrades, there are still three analysts who have rated the stock with a sell rating, indicating some skepticism about its future performance.
  • Barclays and Morgan Stanley have issued "underweight" ratings, suggesting that they believe the stock may not perform as well as the market average.
  • The price-to-earnings ratio of 17.94, while reasonable, may indicate that the stock is not undervalued compared to its peers, which could limit upside potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$237.22 billion
P/E Ratio
19.10
Consensus Rating
Hold
Consensus Price Target
$123.38 (+9.9% Upside)
Volume
1.24 million shares
Average Volume
1.58 million shares
Today's Range
$111.77
$112.51
50-Day Range
$101.80
$114.35
52-Week Range
$96.06
$120.92
Dividend Yield
2.39%
Abbott Laboratories stock logo

7. Abbott Laboratories NYSE:ABT

$135.18 -0.37 (-0.27%)
As of 03:59 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $129, which is significantly below its one-year high of $141.23, indicating potential for growth.
  • Abbott Laboratories reported a strong earnings per share (EPS) of $1.09 for the latest quarter, surpassing analysts' expectations, which reflects solid financial performance.
  • The company has a robust net margin of approximately 31.95%, suggesting efficient management and profitability.

Cons of Abbott Laboratories

  • The revenue for the latest quarter was slightly below analysts' expectations, at $10.36 billion compared to the forecast of $10.38 billion, which may raise concerns about future growth.
  • Despite a healthy current ratio of 1.60, indicating good short-term financial health, the quick ratio of 1.14 suggests that the company may have some reliance on inventory to meet short-term obligations.
  • The debt-to-equity ratio of 0.32 indicates a relatively low level of debt, but it also means that the company may not be leveraging debt effectively to fuel growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$235.19 billion
P/E Ratio
17.67
Consensus Rating
Moderate Buy
Consensus Price Target
$142.59 (+5.5% Upside)
Volume
6.46 million shares
Average Volume
6.13 million shares
Today's Range
$134.54
$135.83
50-Day Range
$123.63
$135.52
52-Week Range
$99.71
$141.23
Dividend Yield
1.83%
AstraZeneca stock logo

8. AstraZeneca NASDAQ:AZN

$69.92 +0.23 (+0.33%)
As of 04:00 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • The current stock price is around $67.72, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
  • AstraZeneca reported a strong quarterly earnings performance, with earnings per share surpassing analysts' expectations, indicating robust financial health and operational efficiency.
  • The company has a solid market capitalization of approximately $210 billion, reflecting its significant presence and stability in the biopharmaceutical industry.

Cons of AstraZeneca

  • The stock has experienced a decline of about 1.8% recently, which may indicate short-term volatility and investor uncertainty.
  • AstraZeneca's current ratio is below 1, suggesting potential liquidity issues, as it may not have enough short-term assets to cover its short-term liabilities.
  • The company has a relatively high price-to-earnings (P/E) ratio, which could imply that the stock is overvalued compared to its earnings, making it a riskier investment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$216.84 billion
P/E Ratio
30.94
Consensus Rating
Buy
Consensus Price Target
$88.00 (+25.9% Upside)
Volume
4.30 million shares
Average Volume
5.18 million shares
Today's Range
$69.56
$70.43
50-Day Range
$64.87
$77.60
52-Week Range
$61.24
$87.68
Dividend Yield
3.03%
Intuitive Surgical stock logo

9. Intuitive Surgical NASDAQ:ISRG

$557.16 -4.47 (-0.80%)
As of 04:00 PM Eastern

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The current stock price is around $561, which reflects a strong market position and potential for growth.
  • Intuitive Surgical, Inc. reported earnings per share (EPS) of $1.81, exceeding analysts' expectations, indicating robust financial performance.
  • The company has a high net margin, suggesting efficient operations and profitability, which can lead to higher returns for investors.

Cons of Intuitive Surgical

  • The stock has experienced fluctuations, with a 52-week high of $616 and a low of $379, indicating volatility that may concern risk-averse investors.
  • The price-to-earnings (PE) ratio is relatively high at 87.49, which may suggest that the stock is overvalued compared to its earnings.
  • Recent insider sales, while sometimes seen as a positive sign, can also raise concerns about executives' confidence in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$199.70 billion
P/E Ratio
86.92
Consensus Rating
Moderate Buy
Consensus Price Target
$598.95 (+7.5% Upside)
Volume
1.23 million shares
Average Volume
1.64 million shares
Today's Range
$553.00
$558.00
50-Day Range
$451.58
$565.94
52-Week Range
$395.60
$616.00
Dividend Yield
N/A
Merck & Co., Inc. stock logo

10. Merck & Co., Inc. NYSE:MRK

$77.92 +0.69 (+0.89%)
As of 03:58 PM Eastern

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $76, which may present a buying opportunity for investors looking for value.
  • Merck has a strong market capitalization of approximately $191 billion, indicating a solid position in the pharmaceutical industry.
  • Institutional investors own over 76% of Merck's stock, suggesting confidence in the company's long-term prospects.

Cons of Merck & Co., Inc.

  • Merck's stock has experienced fluctuations, with a 12-month high of $134.63 and a low of $73.31, indicating volatility that may concern risk-averse investors.
  • Recent insider selling, including a senior vice president selling over 4,000 shares, could signal a lack of confidence among company executives.
  • The company's debt-to-equity ratio of 0.79 suggests a moderate level of debt, which could impact financial stability in uncertain market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$195.66 billion
P/E Ratio
11.58
Consensus Rating
Moderate Buy
Consensus Price Target
$109.19 (+40.1% Upside)
Volume
13.26 million shares
Average Volume
12.45 million shares
Today's Range
$77.42
$79.18
50-Day Range
$73.46
$94.84
52-Week Range
$73.31
$134.63
Dividend Yield
4.33%
Boston Scientific stock logo

11. Boston Scientific NYSE:BSX

$106.52 -0.14 (-0.13%)
As of 03:58 PM Eastern

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The company recently reported strong quarterly earnings, exceeding analyst expectations with a significant increase in revenue, indicating robust business performance.
  • Boston Scientific Co. has a diverse product portfolio in the medical device sector, which positions it well for growth across various interventional medical specialties.
  • The current stock price is around $102.81, reflecting a stable market position and potential for future appreciation.

Cons of Boston Scientific

  • Insider selling has been significant, with executives recently selling large amounts of stock, which may indicate a lack of confidence in the company's short-term prospects.
  • The stock has experienced fluctuations, with a recent trading volume lower than its average, suggesting potential volatility in the market.
  • Despite strong earnings, the company's high price-to-earnings (P/E) ratio indicates that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$157.59 billion
P/E Ratio
85.22
Consensus Rating
Buy
Consensus Price Target
$114.74 (+7.7% Upside)
Volume
7.91 million shares
Average Volume
6.38 million shares
Today's Range
$105.30
$106.67
50-Day Range
$89.78
$106.61
52-Week Range
$71.88
$107.36
Dividend Yield
N/A
Thermo Fisher Scientific stock logo

12. Thermo Fisher Scientific NYSE:TMO

$413.47 -0.45 (-0.11%)
As of 03:58 PM Eastern

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $607.43, which reflects a strong market position and potential for growth.
  • Thermo Fisher Scientific Inc. reported a quarterly revenue of $10.36 billion, exceeding expectations, indicating robust demand for its products and services.
  • The company has a solid return on equity of 17.51%, suggesting effective management and profitability, which can lead to higher shareholder returns.

Cons of Thermo Fisher Scientific

  • Analysts have varied price targets, with some lowering their expectations, which may indicate uncertainty about future performance.
  • The company’s stock has experienced fluctuations, with a twelve-month high of $627.88 and a low of $401.75, suggesting volatility that could deter risk-averse investors.
  • Despite recent revenue growth, the overall market conditions and economic factors could impact future earnings negatively.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$156.08 billion
P/E Ratio
25.01
Consensus Rating
Moderate Buy
Consensus Price Target
$607.43 (+46.9% Upside)
Volume
2.14 million shares
Average Volume
1.84 million shares
Today's Range
$409.89
$415.40
50-Day Range
$402.93
$523.44
52-Week Range
$390.50
$627.88
Dividend Yield
0.40%
Stryker stock logo

13. Stryker NYSE:SYK

$389.30 -5.39 (-1.37%)
As of 03:59 PM Eastern

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The current stock price is around $386, which reflects a strong market position and potential for growth.
  • Fifteen analysts have assigned a buy rating to Stryker Co., indicating strong confidence in the company's future performance.
  • The company has a market capitalization of approximately $147.49 billion, showcasing its significant size and stability in the medical technology sector.

Cons of Stryker

  • The stock has experienced a slight decline of about 0.3% recently, which may indicate short-term volatility.
  • High price-to-earnings (P/E) ratio of 49.80 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Recent insider sales, including a significant sale by a director, could raise concerns about the company's future prospects and insider confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$148.59 billion
P/E Ratio
50.17
Consensus Rating
Moderate Buy
Consensus Price Target
$427.05 (+9.7% Upside)
Volume
1.05 million shares
Average Volume
1.35 million shares
Today's Range
$387.99
$393.32
50-Day Range
$336.96
$394.63
52-Week Range
$314.93
$406.19
Dividend Yield
0.86%
Amgen stock logo

14. Amgen NASDAQ:AMGN

$275.01 -0.84 (-0.30%)
As of 04:00 PM Eastern

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $293, which reflects a strong position in the market and potential for growth.
  • Amgen Inc. has announced a quarterly dividend of $2.38, translating to an annualized dividend of $9.52, providing a yield of approximately 3.52%, which can be attractive for income-focused investors.
  • The company maintains a payout ratio of 86.86%, indicating a commitment to returning value to shareholders while still retaining enough earnings for growth and development.

Cons of Amgen

  • Insider ownership is relatively low at 0.76%, which may indicate a lack of alignment between management and shareholder interests.
  • Recent insider sales, including a significant transaction where an executive sold over 25,000 shares, could raise concerns about the company's short-term outlook.
  • The high payout ratio of 86.86% may limit the company's ability to reinvest in growth opportunities, potentially affecting long-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$147.87 billion
P/E Ratio
36.43
Consensus Rating
Hold
Consensus Price Target
$309.22 (+12.4% Upside)
Volume
2.18 million shares
Average Volume
2.79 million shares
Today's Range
$274.28
$276.90
50-Day Range
$262.28
$318.65
52-Week Range
$253.30
$346.85
Dividend Yield
3.63%
Danaher stock logo

15. Danaher NYSE:DHR

$197.68 +1.27 (+0.65%)
As of 03:59 PM Eastern

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • Danaher Co. has a strong consensus rating of "Moderate Buy" from analysts, indicating positive sentiment and potential for stock appreciation.
  • The current stock price is around $196.60, which may present a buying opportunity for investors looking to enter at a lower price point compared to its fifty-two week high of $281.70.
  • Danaher Co. has a solid dividend payout ratio of approximately 24.85%, suggesting a commitment to returning value to shareholders through dividends.

Cons of Danaher

  • The stock has experienced volatility, with a fifty-day moving average of $197.83 and a significant difference from its 200-day moving average of $218.54, which may indicate uncertainty in the stock's performance.
  • Danaher Co. has a relatively high price-to-earnings (P/E) ratio of 37.23, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Recent insider selling, including a significant transaction by an executive vice president, may raise concerns about the company's future performance and insider confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$141.47 billion
P/E Ratio
37.44
Consensus Rating
Moderate Buy
Consensus Price Target
$264.40 (+33.8% Upside)
Volume
2.87 million shares
Average Volume
3.45 million shares
Today's Range
$195.44
$198.16
50-Day Range
$173.85
$212.97
52-Week Range
$171.00
$281.70
Dividend Yield
0.67%
Gilead Sciences stock logo

16. Gilead Sciences NASDAQ:GILD

$109.11 +2.95 (+2.78%)
As of 04:00 PM Eastern

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The current stock price is around $107, which reflects a strong performance in the biopharmaceutical sector.
  • Gilead Sciences, Inc. reported earnings per share of $1.81, exceeding analysts' expectations, indicating robust financial health and effective management.
  • The company has a solid return on equity of 31.63%, suggesting that it is efficient in generating profits from its equity investments.

Cons of Gilead Sciences

  • The company's revenue for the latest quarter was down 0.3% compared to the same quarter last year, which may raise concerns about its growth trajectory.
  • Gilead Sciences, Inc. has a net margin of only 1.67%, indicating that a relatively small portion of its revenue is converted into profit, which could limit financial flexibility.
  • Analysts forecast earnings per share of 7.95 for the current fiscal year, which may not meet investor expectations if the company fails to achieve this target.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$135.73 billion
P/E Ratio
294.89
Consensus Rating
Moderate Buy
Consensus Price Target
$110.55 (+1.3% Upside)
Volume
10.71 million shares
Average Volume
7.69 million shares
Today's Range
$105.76
$109.26
50-Day Range
$96.86
$113.35
52-Week Range
$62.07
$119.96
Dividend Yield
3.15%
Pfizer stock logo

17. Pfizer NYSE:PFE

$23.51 +0.51 (+2.22%)
As of 03:58 PM Eastern

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $22.86, which is relatively low compared to its one-year high of $31.54, suggesting potential for price appreciation.
  • Pfizer Inc. has a strong market capitalization of approximately $130 billion, indicating a solid position in the biopharmaceutical industry.
  • The company recently reported earnings per share of $0.92, exceeding analysts' expectations, which reflects strong operational performance.

Cons of Pfizer

  • The company has a relatively high dividend payout ratio of 124.64%, which may not be sustainable in the long term if earnings do not grow.
  • Pfizer Inc. experienced a revenue decline of 7.8% compared to the same quarter last year, raising concerns about its growth trajectory.
  • The stock has a beta of 0.58, indicating lower volatility compared to the market, which may limit potential gains during bullish market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$133.66 billion
P/E Ratio
16.67
Consensus Rating
Moderate Buy
Consensus Price Target
$29.17 (+24.1% Upside)
Volume
56.98 million shares
Average Volume
40.95 million shares
Today's Range
$23.16
$23.70
50-Day Range
$21.57
$26.31
52-Week Range
$20.92
$31.54
Dividend Yield
7.52%
Sanofi stock logo

18. Sanofi NASDAQ:SNY

$52.89 +0.61 (+1.17%)
As of 04:00 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi has recently increased its annual dividend to $2.0369, reflecting a strong commitment to returning value to shareholders, with a dividend yield of approximately 3.1%.
  • The current stock price is around $54.18, which is positioned well within its twelve-month range, suggesting potential for growth as it approaches its high of $60.12.
  • Analysts have a consensus rating of "Buy" for Sanofi, indicating positive sentiment in the market, with a price target averaging $63.33, suggesting room for appreciation.

Cons of Sanofi

  • Sanofi's quarterly revenue was down 11.0% year-over-year, which may raise concerns about its growth trajectory and market competitiveness.
  • The company has a relatively low beta of 0.55, indicating less volatility compared to the market, which might limit potential high returns for aggressive investors.
  • Despite a strong EPS report, the previous year's EPS was significantly higher at $1.78, suggesting a decline in profitability that could affect investor confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$133.61 billion
P/E Ratio
21.24
Consensus Rating
Buy
Consensus Price Target
$63.33 (+19.7% Upside)
Volume
1.22 million shares
Average Volume
2.37 million shares
Today's Range
$52.52
$53.00
50-Day Range
$49.21
$59.11
52-Week Range
$45.80
$60.12
Dividend Yield
3.16%
Vertex Pharmaceuticals stock logo

19. Vertex Pharmaceuticals NASDAQ:VRTX

$447.18 +6.52 (+1.48%)
As of 04:00 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The current stock price is around $432, which may present a buying opportunity for investors looking for potential growth.
  • Vertex Pharmaceuticals Incorporated has received multiple "buy" ratings from analysts, indicating strong confidence in the company's future performance.
  • The company has a solid market capitalization of approximately $110.94 billion, suggesting stability and a strong position in the market.

Cons of Vertex Pharmaceuticals

  • The stock has experienced a recent decline of about 1.7%, which may raise concerns about short-term volatility.
  • Insider selling has occurred, with executives reducing their positions, which can sometimes signal a lack of confidence in the company's near-term prospects.
  • The company has a negative price-to-earnings ratio, indicating that it may not be currently profitable, which can be a red flag for some investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$114.83 billion
P/E Ratio
-203.26
Consensus Rating
Moderate Buy
Consensus Price Target
$515.04 (+15.2% Upside)
Volume
1.51 million shares
Average Volume
1.41 million shares
Today's Range
$440.81
$448.00
50-Day Range
$421.16
$513.76
52-Week Range
$377.85
$519.88
Dividend Yield
N/A
Medtronic stock logo

20. Medtronic NYSE:MDT

$86.19 -0.78 (-0.90%)
As of 03:58 PM Eastern

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • Medtronic plc recently reported earnings per share (EPS) of $1.39, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • The current stock price is around $84, which is near its 52-week low, suggesting a potential buying opportunity for investors looking for value.
  • With a current ratio of 1.90, Medtronic plc demonstrates strong liquidity, meaning it has sufficient assets to cover its short-term liabilities, which is a positive sign for financial stability.

Cons of Medtronic

  • The company has a relatively high payout ratio of 85.11%, which may raise concerns about sustainability in dividend payments if earnings do not grow as expected.
  • Despite beating EPS estimates, Medtronic plc's revenue of $8.29 billion fell short of expectations, which could indicate challenges in meeting future growth targets.
  • With a debt-to-equity ratio of 0.48, while manageable, it suggests that the company is somewhat reliant on debt financing, which could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$110.54 billion
P/E Ratio
26.20
Consensus Rating
Hold
Consensus Price Target
$96.14 (+11.5% Upside)
Volume
9.25 million shares
Average Volume
6.76 million shares
Today's Range
$85.39
$86.87
50-Day Range
$81.64
$93.30
52-Week Range
$75.96
$96.25
Dividend Yield
3.29%
Bristol-Myers Squibb stock logo

21. Bristol-Myers Squibb NYSE:BMY

$47.84 +0.62 (+1.31%)
As of 03:58 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol-Myers Squibb

Pros of Bristol-Myers Squibb

  • The current stock price is around $58, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Bristol-Myers Squibb has a strong portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers and autoimmune diseases, which can drive future revenue growth.
  • The company offers a substantial annualized dividend of $2.48, providing a yield of approximately 5.35%, which can be attractive for income-focused investors.

Cons of Bristol-Myers Squibb

  • The dividend payout ratio is high at 92.88%, which may raise concerns about the sustainability of the dividend if earnings do not grow sufficiently.
  • Some analysts have recently downgraded their price targets for the stock, indicating potential short-term challenges in achieving growth.
  • With a significant number of analysts rating the stock as "Hold," there may be limited upside potential in the near term, suggesting a lack of strong bullish sentiment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$97.36 billion
P/E Ratio
-10.82
Consensus Rating
Hold
Consensus Price Target
$58.00 (+21.2% Upside)
Volume
12.59 million shares
Average Volume
13.22 million shares
Today's Range
$47.47
$48.26
50-Day Range
$44.06
$61.09
52-Week Range
$39.35
$63.33
Dividend Yield
5.32%
Elevance Health stock logo

22. Elevance Health NYSE:ELV

$412.49 +8.68 (+2.15%)
As of 03:58 PM Eastern

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$93.20 billion
P/E Ratio
16.11
Consensus Rating
Moderate Buy
Consensus Price Target
$510.38 (+23.7% Upside)
Volume
1.22 million shares
Average Volume
1.51 million shares
Today's Range
$403.32
$412.96
50-Day Range
$375.07
$452.70
52-Week Range
$357.45
$567.26
Dividend Yield
1.75%
HCA Healthcare stock logo

23. HCA Healthcare NYSE:HCA

$385.95 -0.94 (-0.24%)
As of 03:59 PM Eastern

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • HCA Healthcare, Inc. recently reported strong earnings, with earnings per share significantly exceeding analyst expectations, indicating robust financial performance.
  • The company has a high return on equity, showcasing its efficiency in generating profits from shareholders' equity, which is attractive to investors.
  • HCA Healthcare, Inc. has declared a quarterly dividend of $0.72 per share, reflecting a commitment to returning value to shareholders, with an annualized dividend yield of approximately 0.78%.

Cons of HCA Healthcare

  • Despite strong earnings, the stock has experienced price reductions in analyst price targets, indicating potential concerns about future growth prospects.
  • The dividend payout ratio is relatively low, which may suggest that the company is retaining a significant portion of its earnings for reinvestment rather than returning it to shareholders.
  • There is a notable percentage of institutional ownership, which can lead to volatility if large investors decide to sell their positions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$92.85 billion
P/E Ratio
17.57
Consensus Rating
Moderate Buy
Consensus Price Target
$381.13 (-1.2% Downside)
Volume
1.36 million shares
Average Volume
1.43 million shares
Today's Range
$384.00
$388.12
50-Day Range
$314.71
$387.49
52-Week Range
$289.98
$417.14
Dividend Yield
0.78%
McKesson stock logo

24. McKesson NYSE:MCK

$719.07 -7.33 (-1.01%)
As of 03:58 PM Eastern

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $723, reflecting a strong performance in the market and indicating investor confidence.
  • Recent earnings reports show that McKesson Co. exceeded earnings expectations, reporting $10.12 per share, which is a significant increase from the previous year.
  • Analysts have a consensus rating of "Moderate Buy" for McKesson Co., with multiple firms raising their target prices, suggesting positive future growth potential.

Cons of McKesson

  • Despite strong earnings, McKesson Co. reported revenue that fell short of analyst estimates, which could raise concerns about future sales performance.
  • The company has a negative return on equity, which indicates that it is not generating profit effectively from its equity base.
  • Market volatility could impact McKesson Co.'s stock price, as evidenced by fluctuations in trading volume and price movements.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$89.96 billion
P/E Ratio
32.92
Consensus Rating
Moderate Buy
Consensus Price Target
$686.69 (-4.5% Downside)
Volume
809,495 shares
Average Volume
916,062 shares
Today's Range
$717.17
$731.00
50-Day Range
$642.65
$726.05
52-Week Range
$464.42
$730.42
Dividend Yield
0.40%
The Cigna Group stock logo

25. The Cigna Group NYSE:CI

$324.75 +2.79 (+0.87%)
As of 03:58 PM Eastern

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about The Cigna Group

Pros of The Cigna Group

  • The current stock price is around $362, reflecting a strong performance and potential for growth as analysts have set a consensus price target of approximately $379.33.
  • Recent analyst ratings show a positive outlook, with sixteen analysts giving a buy rating and three assigning a strong buy rating, indicating strong confidence in the company's future performance.
  • The Cigna Group has a diverse range of insurance and related products, which can provide stability and growth opportunities in various market conditions.

Cons of The Cigna Group

  • Insiders sold 43,751 shares valued at over $13 million in the last three months, which could signal a lack of confidence in the company's short-term performance.
  • Some analysts have downgraded their ratings, with one firm reducing its target price to $323, indicating potential concerns about the company's growth prospects.
  • The insurance market can be highly competitive and subject to regulatory changes, which may impact The Cigna Group's profitability and market share.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$86.75 billion
P/E Ratio
26.53
Consensus Rating
Buy
Consensus Price Target
$379.33 (+16.8% Upside)
Volume
1.33 million shares
Average Volume
1.71 million shares
Today's Range
$322.36
$325.48
50-Day Range
$301.90
$340.21
52-Week Range
$262.03
$370.83
Dividend Yield
1.96%
CVS Health stock logo

26. CVS Health NYSE:CVS

$63.73 +0.95 (+1.51%)
As of 03:58 PM Eastern

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. has received multiple upgrades from analysts, with recent ratings indicating a strong buy sentiment, suggesting confidence in the company's future performance.
  • The current stock price is around $60, which may present a buying opportunity for investors looking for value in a well-rated stock.
  • Analysts have set a consensus price target of approximately $74.94, indicating potential upside from the current trading levels.

Cons of CVS Health

  • Despite positive ratings, the stock has experienced fluctuations, with recent trading showing a decline, which may raise concerns about short-term volatility.
  • Insider selling activity, such as the recent sale by a senior vice president, could be interpreted as a lack of confidence in the stock's near-term performance.
  • The company's current ratio and quick ratio are below 1, indicating potential liquidity issues that could affect its ability to meet short-term obligations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$80.62 billion
P/E Ratio
17.41
Consensus Rating
Moderate Buy
Consensus Price Target
$75.27 (+18.1% Upside)
Volume
7.39 million shares
Average Volume
11.41 million shares
Today's Range
$62.66
$64.09
50-Day Range
$60.03
$70.40
52-Week Range
$43.56
$72.51
Dividend Yield
4.40%
GSK stock logo

27. GSK NYSE:GSK

$38.38 +0.42 (+1.11%)
As of 03:58 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $36, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • GSK plc recently reported strong quarterly earnings, with earnings per share exceeding expectations, indicating robust financial performance.
  • The company has a solid market capitalization of approximately $74.87 billion, reflecting its stability and presence in the market.

Cons of GSK

  • Analysts have mixed ratings on GSK plc, with some firms issuing a "strong sell" rating, which may indicate potential risks in the stock's performance.
  • The company has a relatively high debt-to-equity ratio of 1.12, suggesting that it relies significantly on debt financing, which can be a concern during economic downturns.
  • Despite recent revenue growth, the net margin of 8.13% may not be as high as some competitors, indicating potential challenges in profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$79.19 billion
P/E Ratio
24.14
Consensus Rating
Hold
Consensus Price Target
$40.58 (+5.7% Upside)
Volume
2.75 million shares
Average Volume
4.84 million shares
Today's Range
$37.98
$38.45
50-Day Range
$33.65
$40.35
52-Week Range
$31.72
$45.80
Dividend Yield
4.26%
Zoetis stock logo

28. Zoetis NYSE:ZTS

$163.63 -0.31 (-0.19%)
As of 03:59 PM Eastern

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $163, which reflects a stable position in the market and may present a buying opportunity for investors looking for growth.
  • Zoetis Inc. has received multiple positive ratings from analysts, with a consensus rating of "Buy" and an average target price of $212.75, indicating strong potential for price appreciation.
  • The company reported earnings per share (EPS) of $1.48, exceeding analyst expectations, which demonstrates strong financial performance and effective management.

Cons of Zoetis

  • Insider selling activity has been noted, with a director selling shares, which could indicate a lack of confidence in the stock's short-term performance.
  • The company has a relatively high price-to-earnings (P/E) ratio of around 29.80, which may suggest that the stock is overvalued compared to its earnings, potentially limiting future price growth.
  • Zoetis Inc. has a debt-to-equity ratio of 1.09, indicating that the company has a significant amount of debt relative to its equity, which could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$72.85 billion
P/E Ratio
29.91
Consensus Rating
Buy
Consensus Price Target
$212.75 (+30.0% Upside)
Volume
1.78 million shares
Average Volume
2.51 million shares
Today's Range
$163.16
$164.85
50-Day Range
$144.09
$165.39
52-Week Range
$139.70
$200.33
Dividend Yield
1.25%
Regeneron Pharmaceuticals stock logo

29. Regeneron Pharmaceuticals NASDAQ:REGN

$614.79 +18.25 (+3.06%)
As of 04:00 PM Eastern

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $594, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
  • Regeneron Pharmaceuticals, Inc. has a strong consensus rating of "Moderate Buy" from analysts, indicating positive sentiment and potential for price appreciation.
  • The company reported a net margin of over 31%, showcasing its ability to generate profit relative to its revenue, which is a positive indicator of financial health.

Cons of Regeneron Pharmaceuticals

  • The company recently missed earnings expectations, reporting $8.22 per share compared to the consensus estimate of $8.83, which may raise concerns about its growth trajectory.
  • Revenue for the last quarter was down about 3.7% compared to the same period last year, indicating potential challenges in maintaining sales growth.
  • Some analysts have downgraded their price targets for the stock, reflecting a cautious outlook on its near-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$66.38 billion
P/E Ratio
16.06
Consensus Rating
Moderate Buy
Consensus Price Target
$890.60 (+44.9% Upside)
Volume
1.10 million shares
Average Volume
790,689 shares
Today's Range
$595.01
$615.45
50-Day Range
$527.78
$680.61
52-Week Range
$520.50
$1,211.20
Dividend Yield
0.15%
Cencora stock logo

30. Cencora NYSE:COR

$292.77 +0.14 (+0.05%)
As of 03:59 PM Eastern

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is around $277, which reflects a strong performance in the market and indicates potential for growth.
  • Recent earnings results showed an earnings per share (EPS) of $4.42, surpassing analysts' expectations, which suggests strong financial health and operational efficiency.
  • The company has a solid revenue growth of 10.3% compared to the same quarter last year, indicating a positive trend in sales and market demand.

Cons of Cencora

  • The company has a high debt-to-equity ratio of 16.40, which may indicate financial risk and reliance on debt financing to support operations.
  • With a current ratio of 0.92, Cencora, Inc. may face challenges in meeting short-term liabilities, suggesting potential liquidity issues.
  • The stock has experienced significant insider selling, with over 50,000 shares sold recently, which could signal a lack of confidence from those closest to the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$56.77 billion
P/E Ratio
41.65
Consensus Rating
Moderate Buy
Consensus Price Target
$301.18 (+2.9% Upside)
Volume
1.54 million shares
Average Volume
1.54 million shares
Today's Range
$291.34
$296.95
50-Day Range
$255.64
$304.04
52-Week Range
$214.77
$309.35
Dividend Yield
0.79%
Becton, Dickinson and Company stock logo

31. Becton, Dickinson and Company NYSE:BDX

$176.72 -0.33 (-0.19%)
As of 03:59 PM Eastern

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The current stock price is around $197, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Becton, Dickinson and Company has a strong presence in the medical supplies and devices market, which is essential for healthcare institutions and has shown resilience during economic fluctuations.
  • Recent insider trading activity indicates confidence in the company's future, as executives have been actively managing their stock positions.

Cons of Becton, Dickinson and Company

  • Recent insider sales have resulted in a notable decrease in ownership percentages, which could signal a lack of confidence among executives regarding the company's short-term performance.
  • The company has experienced fluctuations in stock value, with recent trades reflecting a decrease in positions by insiders, which may raise concerns about future stock performance.
  • With only 0.36% of the stock owned by insiders, there may be limited alignment between management and shareholder interests, potentially impacting decision-making.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.65 billion
P/E Ratio
29.36
Consensus Rating
Hold
Consensus Price Target
$231.44 (+31.0% Upside)
Volume
2.75 million shares
Average Volume
1.92 million shares
Today's Range
$175.62
$177.10
50-Day Range
$165.13
$232.12
52-Week Range
$163.33
$251.99
Dividend Yield
2.43%
Haleon stock logo

32. Haleon NYSE:HLN

$11.01 +0.13 (+1.19%)
As of 03:58 PM Eastern

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The company recently reported earnings per share (EPS) of $0.05, indicating a positive financial performance that may attract investors looking for growth.
  • Haleon plc has a strong return on equity of 14.76%, suggesting effective management and profitability, which can be appealing to potential investors.
  • The business achieved revenue of $3.54 billion during the quarter, surpassing analyst estimates, which reflects strong market demand for its consumer healthcare products.

Cons of Haleon

  • Despite the positive earnings report, the overall market sentiment may be cautious, as some analysts have maintained a "hold" rating on the stock, indicating uncertainty about future performance.
  • The dividend payout ratio is currently at 58.97%, which, while sustainable, may limit the company's ability to reinvest in growth opportunities.
  • Institutional investors and hedge funds own only 6.67% of the company's stock, suggesting a lack of confidence from larger investors, which could impact stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$49.63 billion
P/E Ratio
32.38
Consensus Rating
Moderate Buy
Consensus Price Target
$11.25 (+2.2% Upside)
Volume
22.81 million shares
Average Volume
8.09 million shares
Today's Range
$10.92
$11.05
50-Day Range
$9.28
$10.89
52-Week Range
$8.25
$11.05
Dividend Yield
2.19%
Edwards Lifesciences stock logo

33. Edwards Lifesciences NYSE:EW

$77.82 -0.22 (-0.28%)
As of 03:58 PM Eastern

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The current stock price is around $76.79, which reflects a stable trading performance in recent times.
  • Analysts have assigned an average price target of approximately $79.60, indicating potential upside from the current price.
  • Recent upgrades from analysts, including a shift from a "hold" to a "buy" rating, suggest growing confidence in the company's future performance.

Cons of Edwards Lifesciences

  • One analyst has issued a sell recommendation, indicating some skepticism about the stock's future performance.
  • Despite recent upgrades, the majority of analysts still rate the stock as a "hold," suggesting limited immediate growth potential.
  • The company's price-to-earnings ratio of 10.83 may indicate that the stock is fairly valued, limiting potential for significant gains.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.65 billion
P/E Ratio
11.16
Consensus Rating
Hold
Consensus Price Target
$79.60 (+2.3% Upside)
Volume
5.28 million shares
Average Volume
5.10 million shares
Today's Range
$77.54
$78.37
50-Day Range
$67.04
$78.02
52-Week Range
$58.93
$95.25
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

34. Takeda Pharmaceutical NYSE:TAK

$14.24 +0.01 (+0.07%)
As of 03:58 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is around $15.24, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • Takeda Pharmaceutical Company Limited has shown a strong commitment to research and development, which is crucial for long-term growth in the pharmaceutical industry.
  • The company has a solid return on equity, suggesting effective management and profitability, which can be attractive to investors looking for stable returns.

Cons of Takeda Pharmaceutical

  • The company recently missed earnings estimates by $0.08 EPS, which may raise concerns about its short-term financial performance.
  • Takeda Pharmaceutical Company Limited reported revenue that fell short of consensus estimates, indicating potential challenges in meeting market expectations.
  • With a price-to-earnings ratio of 38.09, the stock may be considered overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.31 billion
P/E Ratio
35.60
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
1.68 million shares
Average Volume
1.92 million shares
Today's Range
$14.14
$14.27
50-Day Range
$13.69
$15.38
52-Week Range
$12.58
$15.43
Dividend Yield
3.82%
Alcon stock logo

35. Alcon NYSE:ALC

$88.03 -1.33 (-1.49%)
As of 03:58 PM Eastern

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $91.50, reflecting a strong performance in the market.
  • Alcon Inc. has shown a positive fifty-two week performance, indicating a growth trend that could attract investors.
  • The company has a relatively low short percentage of float, suggesting that investor confidence is high and there is less risk of a short squeeze.

Cons of Alcon

  • Despite recent positive trends, the average daily volume has decreased, which could indicate reduced trading interest.
  • The month-to-month change in shares shorted has shown a significant decline, which may suggest that some investors are losing confidence.
  • With a days to cover ratio of 2.6, it may take longer for short sellers to cover their positions, indicating potential volatility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.42 billion
P/E Ratio
37.62
Consensus Rating
Moderate Buy
Consensus Price Target
$106.13 (+20.6% Upside)
Volume
1.67 million shares
Average Volume
1.10 million shares
Today's Range
$87.47
$89.41
50-Day Range
$82.86
$98.39
52-Week Range
$80.48
$101.10
Dividend Yield
0.28%
IDEXX Laboratories stock logo

36. IDEXX Laboratories NASDAQ:IDXX

$517.16 -4.52 (-0.87%)
As of 04:00 PM Eastern

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $509, reflecting a strong market position and investor interest.
  • IDEXX Laboratories, Inc. recently reported quarterly earnings that exceeded analysts' expectations, indicating robust financial health and operational efficiency.
  • The company has a high return on equity, showcasing its ability to generate profit from shareholders' equity, which is attractive for potential investors.

Cons of IDEXX Laboratories

  • The stock has a relatively high price-to-earnings ratio, which may indicate that it is overvalued compared to its earnings potential.
  • Market volatility could impact the stock price, as seen with fluctuations in trading volume and price movements.
  • Despite recent upgrades, some analysts still maintain a "hold" rating, suggesting caution among certain investors regarding the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$41.59 billion
P/E Ratio
48.47
Consensus Rating
Moderate Buy
Consensus Price Target
$536.00 (+3.6% Upside)
Volume
606,894 shares
Average Volume
648,678 shares
Today's Range
$513.93
$523.48
50-Day Range
$361.04
$521.68
52-Week Range
$356.14
$545.43
Dividend Yield
N/A
Veeva Systems stock logo

37. Veeva Systems NYSE:VEEV

$240.80 +1.16 (+0.48%)
As of 03:58 PM Eastern

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The current stock price is around $226.20, which may present a buying opportunity for investors looking for growth in the life sciences software sector.
  • Veeva Systems Inc. has a strong position in the market with its cloud-based software solutions tailored for the life sciences industry, including the latest Veeva Commercial Cloud and Veeva Vault products.
  • Insider ownership stands at 10.30%, indicating that executives have a significant stake in the company, which can align their interests with those of shareholders.

Cons of Veeva Systems

  • Recent insider sales totaling 5,869 shares may raise concerns about the executives' confidence in the company's short-term performance.
  • The stock has experienced an 8.32% decrease in the senior vice president's position, which could signal potential volatility or uncertainty in the market.
  • With a significant portion of shares held by insiders, any large sales could impact the stock price negatively, leading to potential losses for other investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.18 billion
P/E Ratio
59.46
Consensus Rating
Moderate Buy
Consensus Price Target
$254.92 (+5.9% Upside)
Volume
1.33 million shares
Average Volume
1.11 million shares
Today's Range
$236.79
$241.10
50-Day Range
$209.34
$242.48
52-Week Range
$170.25
$258.93
Dividend Yield
N/A
Alnylam Pharmaceuticals stock logo

38. Alnylam Pharmaceuticals NASDAQ:ALNY

$291.68 -0.18 (-0.06%)
As of 04:00 PM Eastern

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The current stock price is around $255, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
  • The company reported a significant year-over-year revenue increase of over 20%, indicating strong business growth and demand for its products.
  • Alnylam Pharmaceuticals, Inc. has a solid current ratio of 2.78, suggesting that it has more than enough short-term assets to cover its short-term liabilities, which is a positive indicator of financial health.

Cons of Alnylam Pharmaceuticals

  • The company has a high debt-to-equity ratio of 15.27, indicating that it relies heavily on debt financing, which could pose risks if the company faces financial difficulties.
  • Alnylam Pharmaceuticals, Inc. reported a negative price-to-earnings ratio of -121.64, suggesting that it is currently not profitable, which may deter risk-averse investors.
  • Insider selling has occurred recently, with executives reducing their holdings, which could signal a lack of confidence in the company's short-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$38.03 billion
P/E Ratio
-134.41
Consensus Rating
Moderate Buy
Consensus Price Target
$319.17 (+9.4% Upside)
Volume
627,258 shares
Average Volume
910,836 shares
Today's Range
$288.25
$292.99
50-Day Range
$224.32
$291.86
52-Week Range
$146.79
$304.39
Dividend Yield
N/A
Cardinal Health stock logo

39. Cardinal Health NYSE:CAH

$154.71 +0.85 (+0.55%)
As of 03:58 PM Eastern

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The current stock price is around $148.55, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • Cardinal Health, Inc. has received multiple upgrades from analysts, with Morgan Stanley raising their price target to $166.00, suggesting strong future growth potential.
  • The company recently reported earnings per share (EPS) of $2.35, exceeding analysts' expectations, which demonstrates strong financial performance and operational efficiency.

Cons of Cardinal Health

  • The company has a negative return on equity of 59.57%, indicating that it may not be effectively generating profit from its equity, which could raise concerns about management efficiency.
  • Despite recent revenue growth, Cardinal Health, Inc. reported quarterly revenue that fell short of analysts' expectations, which may signal potential challenges in meeting future financial targets.
  • The stock has a price-to-earnings (P/E) ratio of 27.71, which is relatively high, suggesting that the stock may be overvalued compared to its earnings, potentially limiting upside for new investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.93 billion
P/E Ratio
28.86
Consensus Rating
Moderate Buy
Consensus Price Target
$146.43 (-5.4% Downside)
Volume
1.93 million shares
Average Volume
2.23 million shares
Today's Range
$152.55
$156.44
50-Day Range
$124.87
$154.23
52-Week Range
$93.17
$156.44
Dividend Yield
1.36%
ResMed stock logo

40. ResMed NYSE:RMD

$248.16 -5.19 (-2.05%)
As of 03:58 PM Eastern

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The company has demonstrated strong financial performance, with a recent earnings per share (EPS) of $2.37, slightly exceeding analyst expectations, indicating robust profitability.
  • ResMed Inc. has a solid dividend yield of approximately 0.87%, which can provide a steady income stream for investors, especially given its low dividend payout ratio of 23.79%, suggesting room for future dividend growth.
  • Recent analyst upgrades, including a target price increase to $290.00, reflect positive market sentiment and confidence in the company's growth potential.

Cons of ResMed

  • Despite recent growth, the company faces significant competition in the medical device market, which could impact its market share and pricing power.
  • ResMed Inc. has a relatively high current ratio of 3.33, which, while indicating good short-term liquidity, may suggest inefficiencies in asset utilization that could affect long-term profitability.
  • Recent stock price fluctuations may indicate volatility, which can be a concern for risk-averse investors looking for stable investments.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.39 billion
P/E Ratio
29.30
Consensus Rating
Moderate Buy
Consensus Price Target
$258.83 (+4.3% Upside)
Volume
1.43 million shares
Average Volume
1.02 million shares
Today's Range
$243.20
$251.49
50-Day Range
$204.54
$252.96
52-Week Range
$179.42
$263.05
Dividend Yield
0.86%
argenx stock logo

41. argenx NASDAQ:ARGX

$578.31 +0.21 (+0.04%)
As of 04:00 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenx

Pros of argenx

  • The current stock price is around $563, which may present a buying opportunity for investors looking for growth in the biotech sector.
  • Recent upgrades from analysts, including a shift to an "outperform" rating, indicate positive sentiment and potential for stock appreciation.
  • Institutional ownership stands at over 60%, suggesting confidence from major investors in the company's future performance.

Cons of argenx

  • Despite positive analyst ratings, the stock has experienced volatility, with a twelve-month high of $678.21 and a low of $356.38, indicating potential risk.
  • Some analysts have lowered their price targets, which may signal caution regarding the company's near-term performance.
  • The biotech sector can be highly unpredictable, with regulatory challenges and market competition posing risks to argenx SE's growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.31 billion
P/E Ratio
-657.17
Consensus Rating
Buy
Consensus Price Target
$698.11 (+20.7% Upside)
Volume
316,412 shares
Average Volume
324,855 shares
Today's Range
$572.84
$581.76
50-Day Range
$532.27
$656.65
52-Week Range
$356.38
$678.21
Dividend Yield
N/A
DexCom stock logo

42. DexCom NASDAQ:DXCM

$87.34 +0.38 (+0.44%)
As of 04:00 PM Eastern

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • The current stock price is around $90, which reflects a significant potential for growth given the company's market position and product offerings.
  • DexCom, Inc. has received multiple upgrades from analysts, indicating strong confidence in its future performance, with a consensus price target of approximately $98.11.
  • The company reported a year-over-year revenue increase of 12.5%, showcasing its ability to grow and adapt in the competitive medical device market.

Cons of DexCom

  • The stock has a relatively high price-to-earnings (P/E) ratio of 60.50, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Recent insider selling, including significant shares sold by executives, could signal a lack of confidence in the company's short-term prospects.
  • Despite revenue growth, the company missed earnings expectations in its latest report, which may raise concerns about its ability to meet future financial targets.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.25 billion
P/E Ratio
61.08
Consensus Rating
Moderate Buy
Consensus Price Target
$98.11 (+12.3% Upside)
Volume
2.74 million shares
Average Volume
4.35 million shares
Today's Range
$85.88
$87.65
50-Day Range
$59.83
$86.96
52-Week Range
$57.52
$132.09
Dividend Yield
N/A
GE HealthCare Technologies stock logo

43. GE HealthCare Technologies NASDAQ:GEHC

$71.85 -1.25 (-1.71%)
As of 04:00 PM Eastern

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The current stock price is around $75, which may present a buying opportunity for investors looking for value in the healthcare technology sector.
  • The company recently reported strong quarterly earnings, with earnings per share of $1.01, exceeding analysts' expectations, indicating robust financial performance.
  • GE HealthCare Technologies Inc. has a solid return on equity of 25.74%, suggesting effective management and profitability relative to shareholder equity.

Cons of GE HealthCare Technologies

  • The company has a quick ratio of 0.83, which indicates that it may have difficulty meeting short-term liabilities without selling inventory, potentially raising liquidity concerns.
  • Analysts have recently adjusted their price targets downward, with some firms lowering their expectations for the stock, which could indicate a lack of confidence in future performance.
  • The stock has experienced volatility, with a 52-week range showing a low of $57.65 and a high of $94.80, suggesting potential risks associated with price fluctuations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.90 billion
P/E Ratio
16.59
Consensus Rating
Moderate Buy
Consensus Price Target
$88.27 (+22.9% Upside)
Volume
3.27 million shares
Average Volume
3.41 million shares
Today's Range
$71.79
$73.00
50-Day Range
$58.75
$82.47
52-Week Range
$57.65
$94.80
Dividend Yield
0.19%
Agilent Technologies stock logo

44. Agilent Technologies NYSE:A

$113.48 +0.04 (+0.04%)
As of 03:58 PM Eastern

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The current stock price is around $113.76, which may present a buying opportunity for investors looking for value.
  • Agilent Technologies, Inc. has received a consensus rating of "Moderate Buy" from analysts, indicating positive sentiment towards the stock.
  • The company has a solid dividend yield of 0.87%, which can provide a steady income stream for investors.

Cons of Agilent Technologies

  • Recent target price reductions by analysts, including a drop to $115.00, may indicate concerns about the company's near-term performance.
  • Insider selling activity, such as the recent sale of shares by a director, could signal a lack of confidence in the stock's future performance.
  • The stock has experienced volatility, with a 52-week high of $154.95 and a low of $96.43, which may deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.35 billion
P/E Ratio
26.09
Consensus Rating
Hold
Consensus Price Target
$143.00 (+26.0% Upside)
Volume
2.25 million shares
Average Volume
1.91 million shares
Today's Range
$112.66
$114.14
50-Day Range
$98.97
$123.10
52-Week Range
$96.43
$154.95
Dividend Yield
0.87%
Humana stock logo

45. Humana NYSE:HUM

$255.23 +7.89 (+3.19%)
As of 03:58 PM Eastern

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $249.92, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Humana Inc. reported strong quarterly earnings, with earnings per share significantly exceeding analysts' expectations, indicating robust financial performance.
  • The company has a solid dividend yield of approximately 1.42%, providing a steady income stream for investors.

Cons of Humana

  • The stock has experienced volatility, with a 52-week range indicating significant price fluctuations, which may concern risk-averse investors.
  • Analysts have set varying price targets, with some indicating a potential decline, which could signal uncertainty about the stock's future performance.
  • Humana Inc. operates in a highly competitive market, which may impact its ability to maintain market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.80 billion
P/E Ratio
25.65
Consensus Rating
Hold
Consensus Price Target
$286.81 (+12.4% Upside)
Volume
1.88 million shares
Average Volume
1.77 million shares
Today's Range
$246.48
$255.87
50-Day Range
$226.26
$294.97
52-Week Range
$212.45
$406.46
Dividend Yield
1.56%
Centene stock logo

46. Centene NYSE:CNC

$61.89 +0.34 (+0.55%)
As of 03:58 PM Eastern

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • The current stock price is around $62.82, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Centene Co. reported a significant increase in quarterly revenue, reaching $46.62 billion, which exceeded analysts' expectations and indicates strong business growth.
  • The company has a solid return on equity of 13.85%, suggesting effective management and profitability, which can be attractive to investors seeking reliable returns.

Cons of Centene

  • Despite recent growth, the company has a net margin of only 2.03%, which may raise concerns about profitability and efficiency compared to competitors.
  • Several analysts have downgraded their ratings, with firms like Jefferies Financial Group and Robert W. Baird reducing their price targets, indicating a cautious outlook.
  • The stock has experienced volatility, with a 12-month high of $80.59 and a low of $55.03, which may deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.80 billion
P/E Ratio
9.92
Consensus Rating
Moderate Buy
Consensus Price Target
$79.77 (+28.9% Upside)
Volume
3.25 million shares
Average Volume
4.86 million shares
Today's Range
$61.25
$62.21
50-Day Range
$57.74
$64.37
52-Week Range
$55.03
$80.59
Dividend Yield
N/A
IQVIA stock logo

47. IQVIA NYSE:IQV

$144.90 +1.36 (+0.95%)
As of 03:59 PM Eastern

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The stock has a consensus rating of "Moderate Buy" from analysts, indicating positive sentiment towards its future performance.
  • Recent institutional investments, including a significant purchase of over $10 million by Invenomic Capital Management LP, suggest strong confidence in the company's growth potential.
  • The current stock price is around $145, which may present a buying opportunity for investors looking for value in the medical research sector.

Cons of IQVIA

  • Recent trading activity shows a decline in stock price, with shares down about 5.8% recently, which may indicate market volatility or negative sentiment.
  • Some analysts have downgraded their ratings, with UBS Group lowering their price target significantly, which could reflect concerns about future performance.
  • The company has a relatively high debt-to-equity ratio of 2.12, suggesting that it relies heavily on debt financing, which can be risky in uncertain economic conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$25.07 billion
P/E Ratio
19.32
Consensus Rating
Moderate Buy
Consensus Price Target
$228.14 (+57.4% Upside)
Volume
4.61 million shares
Average Volume
1.53 million shares
Today's Range
$142.87
$145.77
50-Day Range
$140.51
$188.45
52-Week Range
$135.97
$252.88
Dividend Yield
N/A
Mettler-Toledo International stock logo

48. Mettler-Toledo International NYSE:MTD

$1,185.46 +26.36 (+2.27%)
As of 03:58 PM Eastern

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. More about Mettler-Toledo International

Pros of Mettler-Toledo International

  • The current stock price is around $1,158.93, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • Mettler-Toledo International Inc. reported earnings per share of $8.19, surpassing analysts' expectations, which suggests strong financial performance and potential for future growth.
  • The company has a solid market capitalization of approximately $24.09 billion, indicating its stability and ability to invest in growth opportunities.

Cons of Mettler-Toledo International

  • The company experienced a year-over-year revenue decline of 4.6%, which may raise concerns about its growth trajectory and market demand for its products.
  • Mettler-Toledo International Inc. has a negative return on equity of 591.54%, indicating that the company is not generating profit from its equity, which could be a red flag for potential investors.
  • Analysts have set a consensus target price of $1,296.13, which is significantly higher than the current stock price, suggesting that the stock may be undervalued but also indicating potential volatility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$24.64 billion
P/E Ratio
29.25
Consensus Rating
Hold
Consensus Price Target
$1,302.11 (+9.8% Upside)
Volume
354,681 shares
Average Volume
147,888 shares
Today's Range
$1,165.63
$1,191.66
50-Day Range
$969.01
$1,241.57
52-Week Range
$946.69
$1,546.93
Dividend Yield
N/A
STERIS stock logo

49. STERIS NYSE:STE

$250.36 -2.19 (-0.87%)
As of 03:59 PM Eastern

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. More about STERIS

Pros of STERIS

  • STERIS plc has recently seen a significant increase in institutional investment, with D. E. Shaw & Co. Inc. purchasing over 181,000 shares, indicating strong confidence in the company's future performance.
  • The current stock price is around $246, reflecting a robust market capitalization of approximately $24.17 billion, which suggests a stable investment opportunity.
  • Analysts have a consensus rating of "Moderate Buy" for STERIS plc, with several firms raising their price targets, indicating positive growth expectations for the stock.

Cons of STERIS

  • The stock has a relatively high P/E ratio of 52.24, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Despite recent positive analyst ratings, one analyst has issued a "hold" rating, suggesting that there may be concerns about the stock's short-term performance.
  • With 94.69% of the stock owned by institutional investors, there may be less room for retail investors to influence the stock price, which could limit potential gains.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$24.60 billion
P/E Ratio
53.15
Consensus Rating
Moderate Buy
Consensus Price Target
$264.00 (+5.4% Upside)
Volume
673,493 shares
Average Volume
544,476 shares
Today's Range
$249.37
$252.22
50-Day Range
$208.26
$252.31
52-Week Range
$200.98
$252.79
Dividend Yield
0.99%
BioNTech stock logo

50. BioNTech NASDAQ:BNTX

$101.72 +3.92 (+4.01%)
As of 04:00 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. More about BioNTech

Pros of BioNTech

  • The current stock price is around $100, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
  • BioNTech SE recently reported earnings per share of $1.08, significantly exceeding analyst expectations, indicating strong performance and potential for future profitability.
  • The company has a solid market capitalization of approximately $25 billion, suggesting stability and a strong position in the biotechnology market.

Cons of BioNTech

  • The company has reported a negative net margin, indicating that it is currently operating at a loss, which could be a red flag for potential investors.
  • BioNTech SE's revenue has decreased by approximately 19.5% year-over-year, suggesting challenges in maintaining sales growth.
  • Analysts predict that the company will post negative earnings per share for the current year, which may deter investors looking for profitable opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$24.45 billion
P/E Ratio
-48.44
Consensus Rating
Moderate Buy
Consensus Price Target
$142.08 (+39.7% Upside)
Volume
1.81 million shares
Average Volume
935,409 shares
Today's Range
$96.14
$104.56
50-Day Range
$86.65
$120.54
52-Week Range
$76.53
$131.49
Dividend Yield
N/A